Work

Post‐ FDA Approval Experience With Momelotinib in JAK Inhibitor‐Naïve Myelofibrosis: Focus on Anemia Response and Treatment‐Emergent Nephropathy and Peripheral Neuropathy

Year: 2026

Type: article

Abstract: Real-world experience using momelotinib as first-line JAK2 inhibitor therapy in myelofibrosis. Anemia response was moderate (23%) while treatment-emergent adverse events included nephropathy (29%) and peripheral neuropathy (20%).

Source: American Journal of Hematology

DOI: 10.1002/ajh.70203

Authors: Ayalew Tefferi, Maymona Abdelmagid, Jeanne M. Palmer, Aref Al‐Kali, Cecilia Y. Arana Yi, Aasiya Matin, Hassan B. Alkhateeb, Talha Badar, Yassin Bashir, Kaaren K. Reichard, Rong He, Animesh Pardanani, Naseema Gangat

Institutions: Mayo Clinic, Mayo Clinic in Arizona, Mayo Clinic in Florida

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W7119538727

FWCI: 28.71

Cites: 16

Cited by: 7

Related to: